Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s share price rose 5.4% during mid-day trading on Tuesday . The stock traded as high as $16.77 and last traded at $16.50, with a volume of 175,346 shares trading hands. The stock had previously closed at $15.65.

ADMS has been the subject of several analyst reports. Noble Financial reissued a “buy” rating and issued a $25.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, June 28th. JMP Securities initiated coverage on Adamas Pharmaceuticals in a report on Friday, April 1st. They issued an “outperform” rating and a $29.00 price objective for the company. Mizuho boosted their price objective on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Thursday, April 28th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 16th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, June 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $33.60.

The stock’s market capitalization is $349.49 million. The company’s 50-day moving average price is $16.32 and its 200 day moving average price is $16.97.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.11. Equities analysts expect that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current fiscal year.

In other Adamas Pharmaceuticals news, SVP Natalie Mcclure sold 36,000 shares of the firm’s stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $18.50, for a total transaction of $666,000.00. Following the transaction, the senior vice president now owns 21,006 shares of the company’s stock, valued at $388,611. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of Adamas Pharmaceuticals by 585.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 69,411 shares of the specialty pharmaceutical company’s stock valued at $1,966,000 after buying an additional 59,285 shares during the last quarter. EAM Investors LLC purchased a new position in shares of Adamas Pharmaceuticals during the fourth quarter valued at about $4,006,000. Strs Ohio raised its position in shares of Adamas Pharmaceuticals by 46.9% in the fourth quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock valued at $1,127,000 after buying an additional 12,700 shares during the last quarter. Finally, Russell Frank Co raised its position in shares of Adamas Pharmaceuticals by 119.8% in the fourth quarter. Russell Frank Co now owns 83,773 shares of the specialty pharmaceutical company’s stock valued at $2,395,000 after buying an additional 45,652 shares during the last quarter.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.